Janux Therapeutics’ (JANX) Outperform Rating Reiterated at William Blair

William Blair reaffirmed their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research report released on Thursday morning,RTT News reports. William Blair also issued estimates for Janux Therapeutics’ Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($1.28) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($1.74) EPS and FY2027 earnings at ($2.84) EPS.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a report on Thursday, November 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a report on Thursday, November 7th. UBS Group initiated coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 price target for the company. Wedbush restated an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th. Finally, Scotiabank dropped their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $66.44.

Janux Therapeutics Stock Down 4.6 %

Janux Therapeutics stock opened at $48.76 on Thursday. Janux Therapeutics has a 1 year low of $7.79 and a 1 year high of $65.60. The business has a 50 day moving average of $49.76 and a 200-day moving average of $46.38.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. The firm’s revenue was down 82.6% on a year-over-year basis. On average, sell-side analysts anticipate that Janux Therapeutics will post -1.34 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00. Following the completion of the sale, the insider now directly owns 3,162,851 shares in the company, valued at approximately $132,839,742. This represents a 3.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ra Capital Management, L.P. bought 1,200,000 shares of the stock in a transaction dated Friday, October 18th. The shares were acquired at an average price of $44.75 per share, with a total value of $53,700,000.00. Following the completion of the purchase, the director now directly owns 9,317,246 shares of the company’s stock, valued at approximately $416,946,758.50. This represents a 14.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 420,610 shares of company stock valued at $19,288,666 in the last quarter. 29.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Janux Therapeutics

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in Janux Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after acquiring an additional 38,490 shares during the last quarter. Barclays PLC increased its stake in shares of Janux Therapeutics by 496.5% during the third quarter. Barclays PLC now owns 174,061 shares of the company’s stock valued at $7,907,000 after acquiring an additional 144,883 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Janux Therapeutics in the third quarter worth approximately $317,000. Zacks Investment Management grew its position in Janux Therapeutics by 8.7% in the third quarter. Zacks Investment Management now owns 42,133 shares of the company’s stock worth $1,914,000 after buying an additional 3,360 shares during the last quarter. Finally, Readystate Asset Management LP acquired a new position in Janux Therapeutics in the third quarter worth approximately $1,469,000. Institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.